Sponsor:
Minoryx Therapeutics, S.L.
Code:
NCT05819866
Conditions
Cerebral Adrenoleukodystrophy (cALD)
Eligibility Criteria
Sex: Male
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Leriglitazone
Placebo
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations